Biotech chameleons: Quark Pharma aims for $81M IPO
(UPDATED: See below.)
For some reason, biotechnology is rife with chameleons — companies that suddenly and radically alter their scientific strategy, disease focus or business model, sometimes to recover from a major failure, and sometimes just to be whatever faddish investors want them to be.
Today, for instance, Quark Pharmaceuticals — now a Fremont, Calif., developer of drugs that work via a new mechanism known as “RNA interference” — said in an SEC filing that it now… Continue Reading
Bioscrypt acquires 3D facial recognition co., A4Vison, and gets more cash
Toronto, Canada’s Bioscrypt, a provider of technologies that help companies control access to their facilities, said it will acquire A4Vision, the Sunnyvale, Calif. provider of 3D facial imaging and recognition technology.
Concurrent with the completion of the merger, institutional investors associated with A4Vision have agreed to invest between US$6 million and US$8 million in newly issued Bioscrypt common shares and warrants to purchase Bioscrypt common shares. Following completion the acquisition and financing, new and existing… Continue Reading
Theranos raises $28.5M for device tracking effects of drugs on patients
Theranos, a Menlo Park company developing devices that enable healthcare professionals and pharmaceutical companies to track patients’ responses to drugs, has raised $28.5 million of a $30 million planned third round, according to a filing with the Securities and Exchange Commission cited by VentureWire (sub required).
ATA Ventures, Tako Ventures, Draper Fisher Jurvetson and Continental Properties Inc. were listed as investors in the Form D filing received by the SEC on Nov. 17.
The company raised more… Continue Reading